Quarterly report pursuant to Section 13 or 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

v3.23.3
SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 33 Months Ended
Jul. 27, 2022
USD ($)
Apr. 30, 2021
USD ($)
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Oct. 31, 2019
USD ($)
agreement
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Sep. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2023
USD ($)
period
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Collaborations                                
Contingent payments                           $ 1,300,000    
Right to opt out of agreement, different specified times | period                           2    
Upfront payment received   $ 125,000                            
Payment of cost share to collaboration partner                           $ 2,632 $ 12,435  
Revenue recognized                   $ 20,000            
Accounts receivable               $ 23,546   40,320       23,546   $ 23,546
Research and development               6,475     $ 14,666     21,336 44,907  
Intangible asset               14,146   14,949       14,146   14,146
Accounts payable               7,999   22,508       7,999   7,999
Specified Development Events [Member]                                
Collaborations                                
Contingent payments                           279,500    
Specified Regulatory Events [Member]                                
Collaborations                                
Contingent payments                           263,100    
Specified Product Launch Events [Member]                                
Collaborations                                
Contingent payments                           796,000    
Development and regulatory milestones by non-CNS disease products                                
Collaborations                                
Contingent payments                           330,000    
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                                
Collaborations                                
Contingent payments                           100,000    
Development and regulatory milestones by CNS disease products                                
Collaborations                                
Contingent payments                           255,000    
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                                
Collaborations                                
Contingent payments                           150,000    
Grifols                                
Collaborations                                
Upfront payment received           $ 30,000                    
Deferred revenue               0           0   0
Grifols | Research Services                                
Collaborations                                
Revenue recognized                     200       700  
Grifols | Delivery of drug supply for commercialization                                
Collaborations                                
Revenue recognized                     400     2,800 1,600  
Grifols | Commercial milestones                                
Collaborations                                
Contingent payments           $ 297,500                    
Kissei                                
Collaborations                                
Contingent payments             $ 147,000                  
Upfront payment received             $ 33,000                  
Revenue, remaining performance obligation               33,000           33,000   33,000
Knight | Commercial and license agreements                                
Collaborations                                
Upfront payment received                           2,000    
Knight | Maximum | Commercial milestones | Commercial and license agreements                                
Collaborations                                
Contingent payments                           20,000    
Forma                                
Collaborations                                
Upfront fee $ 2,000                              
Research and development                     2,000          
Forma | Commercial milestones                                
Collaborations                                
Potential payments 165,500                              
Forma | Development and regulatory milestones                                
Collaborations                                
Potential payments $ 67,500                              
Forma | Achievement of certain near-term regulatory milestone.                                
Collaborations                                
Research and development                   2,500            
fostamatinib                                
Collaborations                                
Revenue recognized               0     2,500     1,000 2,500 16,000
Government contract     $ 16,500                          
Remaining amount of government award expected to be received in succeeding periods                           500    
fostamatinib | Grifols                                
Collaborations                                
Collaborative payment received       $ 20,000                        
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                                
Collaborations                                
Contingent payments       17,500                        
fostamatinib | Grifols | Creditable advance royalty payment                                
Collaborations                                
Collaborative payment received       $ 2,500                        
fostamatinib | Grifols | Maximum                                
Collaborations                                
Royalty payment as a percentage of net sales           30.00%                    
fostamatinib | Kissei                                
Collaborations                                
Deferred revenue               1,400   1,400       1,400   1,400
Collaborative payment received                       $ 5,000        
Accounts receivable                   20,000            
fostamatinib | Kissei | Delivery of drug supply for commercialization                                
Collaborations                                
Revenue recognized               0           0 2,600  
fostamatinib | Medison                                
Collaborations                                
Revenue recognized               200     0     200 0  
fostamatinib | Medison | Financing arrangement                                
Collaborations                                
Upfront payment received         $ 5,000                      
Financing liability with accreted interest expense               0   0       $ 0   0
Revenue recognized                   5,700            
fostamatinib | Medison | Commercial and license agreements                                
Collaborations                                
Upfront payment received         $ 5,000                      
Number of agreements | agreement         2                      
R552                                
Collaborations                                
Company's percentage of development costs                           20.00%    
Financing component liability               57,900           $ 57,900   57,900
Financing liability interest accretion discount rate                           6.40%    
Financing liability with accreted interest expense               43,600   46,200       $ 43,600   43,600
Accretion expense                           0 700  
Development costs due to collaboration partner               17,700           17,700   17,700
Revenue, remaining performance obligation               67,100           67,100   67,100
R552 | Amended Lilly Agreement                                
Collaborations                                
Funding commitment               22,600           $ 22,600   22,600
Right to opt-back-in co-funding of R552 development, term                           30 days    
R552 | Maximum                                
Collaborations                                
Funding commitment               65,000           $ 65,000   $ 65,000
Non-CNS penetrant IP                                
Collaborations                                
Revenue recognized                         $ 60,400      
CNS penetrant IP                                
Collaborations                                
Revenue recognized               0     0     0 500  
CNS penetrant IP | Licensed Rights                                
Collaborations                                
Revenue, remaining performance obligation                     6,700       6,700  
Royalty | Grifols                                
Collaborations                                
Revenue recognized               800     100     2,300 100  
REZLIDHIA | Forma                                
Collaborations                                
Amortization of intangible assets               300           800    
Royalty expense               $ 400     $ 0     $ 1,000 $ 0  
REZLIDHIA | Forma | FDA approval and first commercial sale of product                                
Collaborations                                
Intangible asset                   15,000            
Accounts payable                   $ 15,000            
Payments of milestone payment obligations                 $ 15,000